CN107011283A - A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives - Google Patents

A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives Download PDF

Info

Publication number
CN107011283A
CN107011283A CN201710400933.3A CN201710400933A CN107011283A CN 107011283 A CN107011283 A CN 107011283A CN 201710400933 A CN201710400933 A CN 201710400933A CN 107011283 A CN107011283 A CN 107011283A
Authority
CN
China
Prior art keywords
prepare compound
solvent
temperature
reaction
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710400933.3A
Other languages
Chinese (zh)
Inventor
邓泽平
陈芳军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Huateng Pharmaceutical Co Ltd
Original Assignee
Hunan Huateng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Huateng Pharmaceutical Co Ltd filed Critical Hunan Huateng Pharmaceutical Co Ltd
Priority to CN201710400933.3A priority Critical patent/CN107011283A/en
Publication of CN107011283A publication Critical patent/CN107011283A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Abstract

The invention discloses the preparation method that a kind of methyl mercapto replaces benzo [d] oxazole derivatives 5 methyl 2 (methyl mercapto) benzo [d] oxazole, using the methylphenol of 2 nitro 4 as initiation material, by reduction, cyclization, methylating obtains target product, and the compound is important medicine intermediate.

Description

A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives
Technical field
The present invention relates to a kind of novel processing step of medicine intermediate, more particularly to a kind of methyl mercapto substitution benzo [d] The preparation method of oxazole derivatives 5- methyl -2- (methyl mercapto) benzo [d] oxazole.
Technical background
Compound methyl mercapto replaces benzo [d] oxazole derivatives 5- methyl -2- (methyl mercapto) benzo [d] oxazole, structural formula For:
This compound methyl mercapto replaces benzo [d] oxazole derivatives 5- methyl -2- (methyl mercapto) benzo [d] oxazole and correlation Derivative in pharmaceutical chemistry and organic synthesis have extensive use.Current methyl mercapto substitution benzo [d] oxazole derivatives Synthesis is more difficult.It is easy to get accordingly, it would be desirable to develop a raw material, it is easy to operate, react easily controllable, overall yield is suitably closed Into method.
The content of the invention
Methyl mercapto substitution benzo [d] oxazole derivatives 5- methyl -2- (methyl mercapto) benzo is prepared the invention discloses one kind The method of [d] oxazole, using 2- nitro-4-methyls phenol as initiation material, by reduction, cyclization, methylating obtains target product 4.Synthesis step is as follows:
(1) using 2- nitro-4-methyls phenol as initiation material, 2 are obtained by reduction reaction;
(2) ring closure reaction is carried out 2, obtains 3;
(3) 3 progress methylation reactions are obtained 4;
In a preferred embodiment, the reducing agent used in described reduction reaction prepare compound 2 is selected from hydrogen;Institute The reagent used in ring closure reaction prepare compound 3 stated is selected from ehtyl potassium xanthate;Described methylation reaction prepare compound 4 Reagent used is selected from dimethyl suflfate.
In a preferred embodiment, the solvent used in described reduction reaction prepare compound 2 is selected from methanol;It is described Ring closure reaction prepare compound 3 used in solvent be selected from pyridine;Solvent used in described methylation reaction prepare compound 4 Selected from water.
In a preferred embodiment, the reaction temperature used in described reduction reaction prepare compound 2 is room temperature;Institute The temperature used in ring closure reaction prepare compound 3 stated is the reflux temperature of solvent;Described methylation reaction prepare compound 4 Temperature used is the backflow of solvent.
Beneficial effects of the present invention:In the present invention examination that methylates is used as using dimethyl suflfate instead of traditional iodomethane Agent, because the volatility of iodomethane is more much bigger than dimethyl suflfate, so using health effect ratio of the iodomethane for operator Dimethyl suflfate is big, and iodomethane is expensive and dimethyl suflfate is cheap, so being conducive to industrial amplification production.Institute To be reduction of the security risk and production cost of operation.
The present invention is further described by the following embodiment, and these descriptions are not present invention to be made into one The restriction of step.It should be understood by those skilled in the art that the equivalent substitution made to the technical characteristic of the present invention, or change accordingly Enter, still fall within protection scope of the present invention.
Specific embodiment mode
Embodiment 1
(1) synthesis of 2- amidos -4- methylphenols
15g 2- nitro-4-methyls phenol and the palladium carbons of 1g 10% are added in 120ml methanol, hydrogen is passed through, room temperature is stirred Mix 8 hours, filter, collect filtrate, concentration obtains 13g 2- amido -4- methylphenols.
(2) synthesis of 5- methyl benzo [d] oxazole -2- (3H)-thiophene ketone
12g 2- amido -4- methylphenols and 18g ehtyl potassium xanthates are added in 180ml pyridines, are heated to reflux stirring Mix 3 hours, be cooled to room temperature, add 10% hydrochloric acid, add ethyl acetate, extraction point liquid is collected organic phase, dried, concentration, Isolated 9g 5- methyl benzo [d] oxazole -2- (the 3H)-thiophene ketone of silicagel column on residue.
(3) synthesis of 5- methyl -2- (methyl mercapto) benzo [d] oxazole
8g 5- methyl benzo [d] oxazole -2- (3H)-thiophene ketone is added in 110ml water, 4g sodium hydroxides are added, then add Enter 12g dimethyl suflfates, be heated to reflux stirring 4 hours, cooling has solid precipitation, filters, 7.1g is obtained with re-crystallizing in ethyl acetate 5- methyl -2- (methyl mercapto) benzo [d] oxazole.

Claims (6)

1. one kind prepares the preparation side that methyl mercapto replaces benzo [d] oxazole derivatives 5- methyl -2- (methyl mercapto) benzo [d] oxazole Method,
Using 2- nitro-4-methyls phenol as initiation material, by reduction, cyclization, methylating obtains target product 4, synthetic route It is as follows,
2. method according to claim 1, it is characterized in that described 3 steps reaction is,
(1) using 2- nitro-4-methyls phenol as initiation material, 2 are obtained by reduction reaction;
(2) ring closure reaction is carried out 2, obtains 3;
(3) 3 progress methylation reactions are obtained 4;
3. method according to claim 1, it is characterised in that the reducing agent choosing used in described reduction reaction prepare compound 2 One from iron powder, zinc powder, hydrogen, sodium borohydride, potassium borohydride, lithium borohydride, sodium cyanoborohydride, lithium aluminium hydride, borine Plant or several mixtures;Reagent used in described ring closure reaction prepare compound 3 is selected from ehtyl potassium xanthate;Described first Reagent used in glycosylation reaction prepare compound 4 is selected from dimethyl suflfate.
4. method according to claim 1, it is characterised in that the solvent used in described reduction reaction prepare compound 2 is selected from Methanol, ethanol, normal propyl alcohol, isopropanol, tetrahydrofuran, dichloromethane, toluene, ortho-xylene, paraxylene, meta-xylene, N, One or more of mixtures in dinethylformamide, DMAC N,N' dimethyl acetamide, triethylamine;Described ring closure reaction system Solvent used in standby compound 3 is selected from methanol, ethanol, normal propyl alcohol, isopropanol, tetrahydrofuran, dichloromethane, toluene, adjacent diformazan It is one or more of mixed in benzene, paraxylene, meta-xylene, N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, pyridine Compound;The described solvent methylated used in anti-prepare compound 4 is selected from water, tetrahydrofuran, dichloromethane, toluene, adjacent diformazan One or more of mixtures in benzene, paraxylene, meta-xylene, N,N-dimethylformamide, DMAC N,N' dimethyl acetamide.
5. method according to claim 1, it is characterised in that the reaction temperature used in described reduction reaction prepare compound 2 It is the reflux temperature of 0 DEG C~solvent;Temperature used in described ring closure reaction prepare compound 3 is the backflow temperature of 0 DEG C~solvent Degree;Temperature used in described methylation reaction prepare compound 4 is the reflux temperature of 0 DEG C~solvent.
6. method according to claim 1, it is characterised in that the reaction temperature used in described reduction reaction prepare compound 2 It is room temperature;Temperature used in described ring closure reaction prepare compound 3 is the reflux temperature of solvent;Described methylation reaction system Temperature used in standby compound 4 is the backflow of solvent.
CN201710400933.3A 2017-05-31 2017-05-31 A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives Pending CN107011283A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710400933.3A CN107011283A (en) 2017-05-31 2017-05-31 A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710400933.3A CN107011283A (en) 2017-05-31 2017-05-31 A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives

Publications (1)

Publication Number Publication Date
CN107011283A true CN107011283A (en) 2017-08-04

Family

ID=59451912

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710400933.3A Pending CN107011283A (en) 2017-05-31 2017-05-31 A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives

Country Status (1)

Country Link
CN (1) CN107011283A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
CN101861311A (en) * 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 The indazole that the 5-pyridone replaces
CN103113321A (en) * 2013-02-27 2013-05-22 南通大学 2-(methylmercapto) benzo [d] oxazole-5-carboxylic acid and preparation method thereof
CN104292179A (en) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 Preparation method of 2-chlorobenzo[d]oxazole-5-formaldehyde
CN107513043A (en) * 2016-06-18 2017-12-26 湖南华腾制药有限公司 A kind of preparation method of bromine substitution benzoxazoles derivative
CN107698534A (en) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 A kind of preparation method of polysubstituted benzo oxazoline compound
CN108129413A (en) * 2016-12-01 2018-06-08 湖南华腾制药有限公司 A kind of preparation method of benzo [d] oxazole derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
CN101861311A (en) * 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 The indazole that the 5-pyridone replaces
CN103113321A (en) * 2013-02-27 2013-05-22 南通大学 2-(methylmercapto) benzo [d] oxazole-5-carboxylic acid and preparation method thereof
CN104292179A (en) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 Preparation method of 2-chlorobenzo[d]oxazole-5-formaldehyde
CN107513043A (en) * 2016-06-18 2017-12-26 湖南华腾制药有限公司 A kind of preparation method of bromine substitution benzoxazoles derivative
CN107698534A (en) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 A kind of preparation method of polysubstituted benzo oxazoline compound
CN108129413A (en) * 2016-12-01 2018-06-08 湖南华腾制药有限公司 A kind of preparation method of benzo [d] oxazole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUERSTENBERG, ALEXANDRE ET AL: "Ultrafast Excited-State Dynamics of DNA Fluorescent Intercalators: New Insight into the Fluorescence Enhancement Mechanism", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》 *

Similar Documents

Publication Publication Date Title
CN103788013B (en) Synthetic method of 2-aryl benzothiazole compounds
CN105218621B (en) Dehydroabietic acid benzimidazole Schiff base heterocyclic derivatives with anti-tumor activity and preparation method therefor and application thereof
CN104292179A (en) Preparation method of 2-chlorobenzo[d]oxazole-5-formaldehyde
CN104710349A (en) Method for purifying etoricoxib
CN101337966A (en) Method for preparing high-purity irinotecan
CN108997305A (en) A kind of new compound 3- methyl -4,5- dichloro-thiophene -2- carboxylic acid and preparation method thereof
CN103601717A (en) Novel preparation method of lenalidomide
CN107011283A (en) A kind of methyl mercapto replaces the preparation method of benzo [d] oxazole derivatives
CN108014113B (en) Application of butyrylamidodimethoxybenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating cervical cancer
CN101003530B (en) Method for preparing perfluoroalkyl group sulfonyl isoflavone of possessing anticarcinogenesis
CN106883227A (en) The method that ergometrine is prepared by ergot fermentation waste
CN108329299B (en) Butyrylamino chloro benzo [ d ] aza-based quinazoline compound, preparation and application thereof
CN108129461B (en) Benzoylaminobenzo [ d ] aza-quinazoline compound, preparation and application thereof
CN108129413A (en) A kind of preparation method of benzo [d] oxazole derivatives
CN104262265B (en) A kind of preparation method of tetrahydro quinazoline derivative
CN104098590B (en) Benzo [1,2-d:5,4-d`] two (azoles)-2,6-two mercaptan and preparation method thereof
CN107698534A (en) A kind of preparation method of polysubstituted benzo oxazoline compound
CN103044345B (en) A kind of synthetic method of 1-(2-hydroxyethyl)-5-sulfydryl-1H-tetrazole
CN107382640A (en) The synthetic method of β aryl phenylpropyl alcohol ketone class compounds
CN106810543A (en) It is a kind of(The base of thiazole 5)The preparation method of benzo [d] oxazole
CN107513043A (en) A kind of preparation method of bromine substitution benzoxazoles derivative
CN106749006A (en) It is a kind of(2 hydroxyl-oxethyls)The preparation method of the alcohol of quinoline 4
CN102617410A (en) Method for purifying 3,4,5,6-tetrahalogenated phenolsulfonphthalein
CN108143736B (en) Application of butyrylaminobenzo [ d ] aza-based quinazoline in preparation of drugs for treating lung cancer
CN108752339B (en) A kind of synthetic method of quindoline and its derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170804

RJ01 Rejection of invention patent application after publication